Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice

Cardiovascular Toxicology

Volumn 5, Issue 1, 2005, Pages 29-41

  Soucy, Nicole V ^a   Mayka, Debra ^a   Klei, Linda R ^a,c   Nemec, Antonia A ^c   Bauer, John A ^b   Barchowsky, Aaron ^a,c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b O   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Angiogenesis; Arsenic; Endothelin 1; Matrigel; Matrix metalloproteinase 9; Neovascularization; Plasminogen activator inhibitor 1; Vascular endothelial cell growth factor

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; DRINKING WATER; ENDOTHELIN 1; GELATINASE B; MATRIGEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GENE INDUCTION; HEART; IMPLANT; IN VIVO STUDY; LONG TERM EXPOSURE; MALE; MICROVASCULATURE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULARIZATION; WATER CONTAMINATION;

EID: 18544372749     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/ct:5:1:029     Document Type: Article

References (49)

1. Engel, R.R., Hopenhayn-Rich, C., Receveur, O., and Smith, A.H. (1994). Vascular effects of chronic arsenic exposure: a review. Epidemiol. Rev. 16:184-208.
2. Tseng, C.H., Chong, C.K., Tseng, C.P., Hsueh, Y.M., Chiou, H.Y., Tseng, C.C., et al. (2003). Long-term arsenic exposure and ischemic heart disease in arseniasis-hyperendemic villages in Taiwan. Toxicol. Lett. 137:15-21.
3. Wang, S.L., Chiou, J.M., Chen, C.J., Tseng, C.H., Chou, W.L., Wang, C.C., et al. (2003). Prevalence of non-insulin-dependent diabetes mellitus and related vascular diseases in southwestern arseniasis-endemic and nonendemic areas in taiwan. Environ. Health Perspect. 111:155-160.
4. Rahman, M., Tondel, M., Ahmad, S.A., Chowdhury, I.A., Faruquee, M.H., and Axelson, O. (1999). Hypertension and arsenic exposure in Bangladesh. Hypertension 33:74-78.
5. Calderon, R.L. (2000). The epidemiology of chemical contaminants of drinking water. Food Chem. Toxicol. 38:S13-S20.
6. Lewis, D.R., Southwick, J.W., Ouellet-Hellstrom, R., Rench, J., and Calderon, R.L. (1999). Drinking water arsenic in Utah: a cohort mortality study. Environ. Health Perspect. 107:359-365.
7. Shaofen, J. and Wai, C.M. (2004). Arsenic in drinking water - a global environmental problem. J. Chem. Educ. 81:207-213.
8. Adachi, M., Iwaki, H., Shindoh, M., Akao, Y., Hachiya, T., Ikeda, M., et al. (1997). Predominant expression of the src homology 2-containing tyrosine phosphatase protein SHP2 in vascular smooth muscle cells. Virchows Arch. 430:321-325.
9. Liu, Z., Shen, J., Carbrey, J.M., Mukhopadhyay, R., Agre, P., and Rosen, B.P. (2002). Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc. Natl. Acad. Sci. USA 99:6053-6058.
10. Oremland, R.S. and Stolz, J.F. (2003). The ecology of arsenic. Science 300:939-944.
11. Aposhian, H.V., Zakharyan, R.A., Avram, M.D., Kopplin, M.J., and Wollenberg, M.L. (2003). Oxidation and detoxification of trivalent arsenic species. Toxicol. Appl. Pharmacol. 193:1-8.
12. Carter, D.E., Aposhian, H.V., and Gandolfi, A.J. (2003). The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol. Appl. Pharmacol. 193:309-334.
13. Barchowsky, A., Roussel, R.R., Klei, L.R., James, P.E., Ganju, N., Smith, K.R., et al. (1999). Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol. Appl. Pharmacol. 159:65-75.
14. Drobna, Z., Jaspers, I., Thomas, D.J., and Styblo, M. (2003). Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J. 17:67-69.
15. Barchowsky, A., Dudek, E.J., Treadwell, M.D., and Wetterhahn, K.E. (1996). Arsenic induces oxidant stress and NF-KappaB activation in cultured aortic endothelial cells. Free Radic. Biol. Med. 21:783-790.
16. Barchowsky, A., Kiel, L.R., Dudek, E.J., Swartz, H.M., and James, P.E. (1999). Stimulation of reactive oxygen, but not reactive nitrogen species, in vascular endothelial cells exposed to low levels of arsenite. Free Radic. Biol. Med. 27:1405-1412.
17. Carmignani, M., Boscolo, P., and Castellino, N. (1985). Metabolic fate and cardiovascular effects of arsenic in rats and rabbits chronically exposed to trivalent and pentavalent arsenic. Arch. Toxicol 8(Suppl.):452-455.
18. Li, Y., Sun, X., Wang, L., Zhou, Z., and Kang, Y.J. (2002). Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc. Toxicol. 2:63-73.
19. Unnikrishnan, D., Dutcher, J.P., Varshneya, N., Lucariello, R., Api, M., Garl, S., et al. (2001). Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97:1514-1516.
20. Drolet, B., Simard, C., and Roden, D.M. (2004). Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109:26-29.
21. Chen, C.J., Chiou, H.Y., Chiang, M.H., Lin, L.J., and Tai, T.Y. (1996). Dose-response relationship between ischemic heart disease mortality and long-term arsenic exposure. Arterioscler. Thromb. Vasc. Biol. 16:504-510.
22. National Research Council. (2001). Arsenic in Drinking Water: Update 2001. National Academy Press, pp. 1-333.
23. Yu, U.S., Lee, C.H., and Chen, G.S. (2002). Peripheral vascular diseases resulting from chronic arsenical poisoning. J. Dermatol. 29:123-130.
24. Rahman, M. (2002). Arsenic and hypertension in Bangladesh. Bull. World Health Organ. 80:173.
25. Abernathy, C.O., Liu, Y.P., Longfellow, D., Aposhian, H.V., Beck, B., Fowler, B., et al. (1999). Arsenic: health effects, mechanisms of actions, and research issues. Environ. Health Perspect. 107:593-597.
26. Lee, M.Y., Jung, B.I., Chung, S.M., Bae, O.N., Lee, J.Y., Park, J.D., et al. (2003). Arsenic-induced dysfunction in relaxation of blood vessels. Environ. Health Perspect. 111:513-517.
27. Soucy, N.V., Ihnat, M.A., Kamat, C.D., Hess, L., Post, M.J., Klei, L.R., et al. (2003). Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicol. Sci. 76:271-279.
28. Carmeliet, P. and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407:249-257.
29. Hayden, M.R. and Tyagi, S.C. (2004). Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc. Diabetol. 3:1-16.
30. Loomans, C.J., Dao, H.H., van Zonneveld, A.J., and Rabelink, T.J. (2004). Is endothelial progenitor cell dysfunction involved in altered angiogenic processes in patients with hypertension? Curr. Hypertens. Rep. 6:51-54.
31. Kao, Y.H., Yu, C.L., Chang, L.W., and Yu, H.S. (2003). Low concentrations of arsenic induce vascular endothelial growth factor and nitric oxide release and stimulate angiogenesis in vitro. Chem. Res. Toxicol. 16:460-468.
32. Roboz, G.J., Dias, S., Lam, G., Lane, W.J., Soignet, S.L., Warrell, R.P. Jr., et al. (2000). Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96:1525-1530.
33. Soucy, N.V., Klei, L.R., Mayka, D.D., and Barchowsky, A. (2004). Signaling pathways for arsenic-stimulated vascular endothelial growth factor-a expression in primary vascular smooth muscle cells. Chem. Res. Toxicol. 17:555-563.
34. Carmignani, M., Boscolo, P., and Iannaccone, A. (1983). Effects of chronic exposure to arsenate on the cardiovascular function of rats. Br. J. Ind. Med. 40:280-284.
35. Bagnato, A. and Spinella, F. (2003). Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol. Metab. 14:44-50.
36. Jiang, S.J., Lin, T.M., Wu, H.L., Han, H.S., and Shi, G.Y. (2002). Decrease of fibrinolytic activity in human endothelial cells by arsenite. Thromb. Res. 105:55-62.
37. Wu, H.L., Yang, W.H., Wang, M.Y., and Shi, G.Y. (1993). Impaired fibrinolysis in patients with Blackfoot disease. Thromb. Res. 72:211-218.
38. Cho, A. and Reidy, M.A. (2002). Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ. Res. 91:845-851.
39. Morishige, K., Shimokawa, H., Matsumoto, Y., Eto, Y., Uwatoku, T., Abe, K., et al. (2003). Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc. Res. 57:572-585.
40. Rossman, T.G., Uddin, A.N., Burns, F.J., and Bosland, M.C. (2002). Arsenite cocarcinogenesis: an animal model derived from genetic toxicology studies. Environ. Health Perspect. 110(Suppl. 5):749-752.
41. Wang, C.H., Jeng, J.S., Yip, P.K., Chen, C.L., Hsu, L.I., Hsueh, Y.M., et al. (2002). Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 105:1804-1809.
42. Simeonova, P.P., Hulderman, T., Harki, D., and Luster, M.I. (2003). Arsenic exposure accelerates atherogenesis in apolipoprotein E(-/-) mice. Environ. Health Perspect. 111:1744-1748.
43. Tang, D.G. and Conti, C.J. (2004). Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization: an update. Semin. Thromb. Hemost. 30:109-117.
44. Rivard, A., Fabre, J.E., Silver, M., Chen, D., Murohara, T., Kearney, M., et al. (1999). Age-dependent impairment of angiogenesis. Circulation 99:111-120.
45. Scotland, R., Vallance, P., and Ahluwalia, A. (1999). Endothelin alters the reactivity of vasa vasorum: mechanisms and implications for conduit vessel physiology and pathophysiology. Br. J. Pharmacol. 128:1229-1234.
46. Galis, Z.S., Johnson, C., Godin, D., Magid, R., Shipley, J.M., Senior, R.M., et al. (2002). Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ. Res. 91:852-859.
47. Schneider, D.J., Ricci, M.A., Taatjes, D.J., Baumann, P.Q., Reese, J.C., Leavitt, B.J., et al. (1997). Changes in arterial expression of fibrinolytic system proteins in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 17:3294-3301.
48. Achanzar, W.E., Brambila, E.M., Diwan, B.A., Webber, M.M., and Waalkes, M.P. (2002). Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J. Natl. Cancer Inst. 94:1888-1891.
49. Koenig, W. (1998). Haemostatic risk factors for cardiovascular diseases. Eur. Heart J. 19(Suppl. C): C39-C43.